AI
Tuesday, November 24, 2015 9:56:13 PM
$SYN..Lancet Neurology Article. Key point/conclusion out today.
.....................................................................
THE LANCET Neurology article is posted on their site
From ... http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(15)00322-1/abstract
Interpretation
Estriol plus glatiramer acetate met our criteria for reducing relapse rates, and treatment was well tolerated over 24 months. These results warrant further investigation in a phase 3 trial.
.....................................................................
THE LANCET Neurology article is posted on their site
From ... http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(15)00322-1/abstract
Interpretation
Estriol plus glatiramer acetate met our criteria for reducing relapse rates, and treatment was well tolerated over 24 months. These results warrant further investigation in a phase 3 trial.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
